The recently discovered GABA B receptor-positive allosteric modulators enhanced the potency and efficacy of GABA B receptor agonists in in vitro experiments. These GABA B modulators also attenuated reward and anxiety in behavioral experiments without causing the untoward side effects associated with GABA B receptor activation by agonist administration and hence exhibited potential therapeutic utility. However, the underlying molecular mechanisms enabling the GABA B allosteric modulators to dissociate from the GABA B agonistic side effects remain elusive. To address this question, we have examined the effects of a typical GABA B modulator, 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)-phenol (CGP7930), on GABA B receptor-mediated modulations of both the excitatory and the delayed inhibitory components of hippocampal CA1 synaptic transmission. Using baclofen as an agonist and a multielectrode recording system, we recorded GABA B receptor-mediated modulations of both the field excitatory postsynaptic potentials and the population spikes simultaneously, as well as the paired-pulse inhibition of the population spike. We found that CGP7930 selectively enhanced the baclofen-induced modulation of synaptic inhibition without having any significant effects on the synaptic excitation. Our experiments have therefore revealed a pathway-selective differential modulation of synaptic transmission by CGP7930. This finding provides a synaptic mechanism to support the hypothesis that GABA B potentiators may be a better therapeutic alternative than GABA B agonists for central nervous system disorders.
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GABA is the most abundant inhibitory neurotransmitter in the central nervous system. It is involved in numerous physiological processes by exerting inhibitory control on neuronal networks via the activation of GABA A and GABA B receptors (GABA A Rs and GABA B Rs). The GABA A Rs are ionotropic receptors and are associated with chloride conductance. They mediate fast synaptic inhibition. The GABA B Rs are G-protein-coupled heterodimeric receptors, composed of subunits designated GABA B(1) and GABA B(2) (Kaupmann et al., 1997 (Kaupmann et al., , 1998 White et al., 1998) . The agonist binding site in the GABA B Rs is limited to the GABA B(1) subunit (Kniazeff et al., 2002) , whereas the GABA B(2) subunit links to G-proteins (Galvez et al., 2001; Uezono et al., 2006) of the pertussis toxin-sensitive family, i.e., G i /G o (Odagaki and Koyama, 2001 ). The recently discovered GABA B R-positive allosteric modulators (Urwyler et al., 2001 (Urwyler et al., , 2003 , exemplified by the compound CGP7930, have been shown to act on the GABA B(2) subunit (Binet et al., 2004) to enhance the binding and the function of GABA B R agonists, GABA or baclofen, without showing any intrinsic agonistic efficacy.
The GABA B Rs exert their inhibitory functions in the central nervous system by increasing potassium conductance postsynaptically to reduce neuronal excitability and by inhibiting calcium conductance presynaptically to reduce neurotransmitter release (for review, see Bowery et al., 2002; Bettler et al., 2004) . The GABA B R agonist baclofen has been used in clinical studies to treat spasticity, pain, and addiction, but the muscle relaxant, hypothermic, and sedative side effects of baclofen, together with patients' increasing tolerance, limit its potential therapeutic utility. Recently, the therapeutic targeting of GABA B Rs has been further exploited by testing the GABA B R-positive allosteric modulators in behavioral models. CGP7930 and another GABA B R-positive allosteric modulator GS39783 have been shown to reduce cocaine self-administration (Smith et al., 2004) , the cocaineinduced lowered intracranial self-stimulation threshold (Slattery et al., 2005) , and anxiety (Cryan et al., 2004) . In these behavioral experiments, the GABA B R potentiators were also shown to be devoid of the typical side effects associated with GABA B R agonists.
To elucidate the mechanisms underlying the anti-addictive actions of the GABA B R potentiators, we have recently shown that CGP7930 can indeed enhance the GABA B R-mediated inhibition of dopamine neuronal activity in the ventral tegmental area (Chen et al., 2005b) . In the present study, we examined the mode of action by the GABA B potentiator CGP7930 on GABA B R-mediated modulations of synaptic transmission in the hippocampal CA1 area.
GABA B Rs are expressed in abundance in the hippocampus, and their modulatory roles in the CA1 synaptic transmission are well described (Nicoll, 2004) . GABA B R activation causes a slow postsynaptic hyperpolarization and the presynaptic inhibition of neurotransmitter release, including autoinhibition of GABA release and heterosynaptic inhibition of Glu release (Thompson and Gahwiler, 1992; Wu and Saggau, 1995) . Using the rat hippocampal CA1 neuronal network, we have dissected out the measures for GABA B R-mediated modulations of both the excitatory and inhibitory synaptic transmission and examined the effects of CGP7930 on these GABA B R-mediated modulations of synaptic transmission. Our results revealed a selective potentiation by CGP7930 of baclofen-induced modulation of synaptic inhibition. Some of these results have previously been published as an abstract (Chen et al., 2005a) .
Materials and Methods
Hippocampal slices were prepared from male Sprague-Dawley rats (25-30 days old), decapitated immediately after the dislocation of the neck, according to the Guidance on the Operation of the Animals (Scientific Procedures) Act 1986 (UK). The brain was quickly removed and immediately immersed in ice-cold artificial cerebrospinal fluid (ACSF), constantly oxygenated with 95% O 2 /5% CO 2 . The composition of the ACSF was 123 mM NaCl, 22 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 , 3.75 mM KCl, 10 mM D-glucose, 2.5 mM CaCl 2 , and 1.2 mM MgSO 4 . Sagittal slices (350 m) were cut on a Campden vibroslicer (Campden Instruments Ltd., Leicester, UK) at 4°C, and slices from the middle third portion of the hippocampus were harvested and placed in an incubation chamber at 27-28°C for at least 1 h before recording. For experiments using 10 M bicuculline, the CA3 area was surgically removed to prevent the spread of spontaneous epileptiform activity in the slice.
One slice was transferred to an MED64 probe (Panasonic, Osaka, Japan), with an interelectrode distance of 150 m. The slice was carefully positioned to have the CA1 area over the 64-electrode array as shown in Fig. 1A . The slice was weighed down with a nylon wire mesh and a tungsten ring, submerged in ACSF saturated by 95% O 2 /5% CO 2 at 31-32°C at a perfusion rate of 1 to 2 ml/min. Of the 64 planar surface electrodes, two positioned in the stratum radiatum were selected for stimulation to activate two Schaffer collateral pathways. A negative electrical pulse of 10 to 70 A with 0.2-ms duration was applied once every 30 s to the two pathways alternately. Recordings of field excitatory postsynaptic potentials (fEPSPs) or the population spikes (PSs) were obtained simultaneously from a number of electrodes positioned in the stratum radiatum and stratum pyramidale, respectively (Fig. 1) , using Performer 2 (Panasonic). Experiments were only conducted when signals recorded adjacent to the stimulation electrodes were comparable with microelectrode recordings, i.e., the amplitude of fEPSPs reached 1 mV and the PS reached 2 mV. The 20 to 80% initial slope and the half-width (HW) of the fEPSP were measured by Performer 2. The amplitude of the PS (the vertical distance from the negative peak to a line drawn between the two positive peaks) was measured offline using pClamp 9 (Axon Instruments, Union City, CA). Recordings that met the criteria of the fEPSP amplitude Ͼ0.2 mV (n ϭ 6 -14 for each experiments) or the PS amplitudes Ͼ0.5 mV (n ϭ 3-6 for each experiment) were selected for analysis, and the averaged results was used as n ϭ 1 experiment (see Fig. 2B ). In averaging multiple recordings from one slice we took into account the variability between recording sites and hence generated highly repeatable results between experiments.
During drug application, a stable control baseline recording was first established for at least 16 min. Test compounds were delivered to the slice via switching from the control ACSF to a drug-containing ACSF, which was continued for 16 min to allow for the drug to reach a plateau effect. The percentage change during drug application over the baseline was then calculated. In experiments in which escalating concentrations of drugs were used without a washing period in between, the plateau values were used for the calculation of percent changes from the initial baseline. Data were only used from experiments in which, after the cumulative applications, the recorded signal values returned to the initial baseline level after a washing period or reversed back by an antagonist. Concentration-response curves were fitted with a sigmoidal function by using SigmaPlot 9.0 (Systat Software UK Ltd., London, UK).
(RS)-Baclofen and CGP55845 were purchased from Tocris Cookson Inc. (Bristol, UK). CGP7930 was synthesized at the Lilly chemistry laboratories (Lilly UK). CGP7930 was dissolved in dimethyl sulfoxide, and the final dimethyl sulfoxide in ACSF is Ͻ0.1%. Numerical data in the text and error bars in figures are expressed as the means Ϯ S.E.M. Statistical comparisons were made with one-way analysis of variance or two-tailed Student's t test, unpaired, or paired when stated.
Results

CGP7930 Did Not Enhance the Baclofen-Induced
Inhibition of Synaptic Excitation. Stimulation of Schaffer collateral-commissural fibers in the stratum radiatum evoked excitatory field potentials recorded by electrodes positioned in the CA1 area as shown in Fig. 1 . The field potentials were completely blocked by 20 M 6-cyano-7-nitroquinoxaline-2,3-dione (data not shown) as they were mediated by the excitatory glutamate receptors (GluRs) in this monosynaptic pathway. The negative initial slopes of the fEPSPs, recorded in the dendritic field of CA1 pyramidal neurons in stratum radiatum, are known to be proportional to the synaptic current influx through GluR channels and were hence used to measure the excitatory synaptic transmission. The PSs recorded in the somatic region of CA1 pyramidal neurons in stratum pyramidale are the summations of action potentials (the negative peak) generated in the soma due to synaptic excitation, with the positively deflected field potentials. The amplitudes of the PS measured from the positive deflection to the negative peak were also used to quantify the excitatory synaptic transmission.
The GABA B R antagonist CGP55845 at 1 or 10 M (n ϭ 11) or the GABA B R potentiator CGP7930 at 30 M (n ϭ 6) caused no significant changes to the fEPSP slope or the PS amplitude, indicating a low tonic level of GABA B receptormediated modulation of synaptic excitation. The GABA B R GABA B Potentiator Selectively Modulates Synaptic Inhibition Fig. 1 . Recordings of hippocampal CA1 field potentials using the MED64 multielectrode recording system. A, microscopic image of a hippocampal slice on the 64-electrode array. B, field potentials recorded by electrodes in the CA1 area. A negative pulse stimulation was applied to electrode 45 positioned in the stratum radiatum to activate the Schaffer collateral-commissural fibers. fEPSPs evoked in the stratum radiatum were recorded by electrodes 33 to 48 (but not 44 and 45), and the PSs were recorded in the pyramidal cell body layer by electrodes 49 to 56. Electrodes 57 to 64 are in the stratum oriens of CA1. Electrode 44 is used as another stimulating electrode. Electrodes 1 to 32 lie outside the CA1 area, and hence, no signals were recorded. The x-axis ranges from 0 to 20 ms and the y-axis from Ϫ2.0 to ϩ1.0 mV. agonist baclofen reduced the GluR-mediated excitatory synaptic transmission and produced concentration-dependent inhibition of the fEPSP slope and the PS amplitude ( Fig. 2) (n ϭ 6, P Ͻ 0.001, one-way analysis of variance), in agreement with previous findings that GABA B R activation can inhibit excitatory synaptic transmission by presynaptic inhibition of glutamate release (Davies et al., 1993; Isaacson et al., 1993; Ziakopoulos et al., 2000) , as well as postsynaptic hyperpolarization of CA1 cells (Newberry and Nicoll, 1984) . Baclofen was applied cumulatively with escalating concentrations at 0.1, 1, 3, and 10 M, followed by full reversal with the antagonist CGP55845 at 1 M ( Fig. 2A) . At the low concentrations of 0.1 and 1 M, baclofen had no effects on the fEPSP slope or the PS amplitude. At the high concentrations of 3 and 10 M, a reduction of up to 70% was achieved by baclofen. The percentage reduction for both the fEPSP and the PS are in good agreement (Fig. 2, B and C, F) .
The GABA B -positive allosteric modulator CGP7930 has been reported to enhance the potency and efficacy of GAB-A B R agonists (Urwyler et al., 2001 ). CGP7930 has also been shown previously by us to potentiate baclofen-induced inhibition of dopamine neuron firing in rat ventral tegmental slices (Chen et al., 2005b ). Here we wanted to see whether CGP7930 is able to enhance the effects of baclofen on CA1 excitatory transmission. The effects of 30 M CGP7930 (Chen et al., 2005b) on baclofen-induced modulation of the fEPSP and the PS were examined in a set of six experiments. CGP7930 was preapplied for 20 min and then coapplied with escalating concentrations of baclofen in the same paradigm as the experiments above. The inhibition caused by baclofen was thus compared between control experiments and experiments with CGP7930 coapplied (Fig. 2) . The baclofen concentration-response curves for the fEPSP slope and the PS amplitude were plotted and fitted with sigmoidal curves. The curves with CGP7930 coapplied were found to be shifted slightly to the left, for both the fEPSP slope (IC 50 of baclofen: 5.7 M for control versus 4.2 M for ϩCGP7930) and the PS amplitude (IC 50 of baclofen: 6.8 M for control versus 3.3 M for ϩCGP7930), but no statistical differences were found (P Ͼ 0.05, n ϭ 6) (Fig. 2, B and C) . A larger shift was observed with the PS amplitude, perhaps due to the fact that more factors can influence the excitability of the cells, including inhibition in the slice. The inability of CGP7930 to shift the baclofen concentration-response curve of the fEPSP slope (Fig. 2B) showed that CGP7930 was not able to potentiate the inhibitory effects of baclofen on synaptic excitation in CA1 cells.
CGP7930 Enhanced the Inhibitory Effects of Baclofen on Synaptic Inhibition. On close examination of the shape of the fEPSP, it was noted that baclofen caused significant widening of the fEPSP by slowing down the returning phase, even at the low concentrations of 0.1 and 1 M Fig. 2 . CGP7930 had no significant effects on CA1 synaptic excitation. A, a typical experiment showing the concentration-dependent effects of baclofen on synaptic excitation measured as the fEPSP slope and the full reversal by the GABA B R antagonist CGP55845. Each recording of the fEPSP in CA1 stratum radiatum was normalized to the average of the control period before baclofen was applied, and an average of all 14 recordings is shown. Representative traces of the fEPSP recordings at different time points and baclofen (Bac) concentrations are shown in the inset. B and C, concentration-response curves of baclofen in the absence (F) and the presence of CGP7930 (E) were constructed by sigmoidal fitting to the averaged percentage control values of the fEPSP slope (B) or the PS amplitude (C) at the corresponding baclofen concentrations (n ϭ 6). No significant differences were found between the curves with or without CGP7930.
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at ASPET Journals on April 13, 2017 jpet.aspetjournals.org baclofen, which did not affect the fEPSP initial slope (Fig.  3A) . It was also noted that the fEPSPs recorded in the stratum radiatum were of a range of HWs (mean ϭ 5.0 ms and S.D. ϭ 1.6 ms, n ϭ 72), with narrow ones recorded proximal to the cell body and wider ones in distal dendritic field. The effects of baclofen on fEPSP HW were analyzed with all the fEPSP recordings (amplitude Ͼ0.2 mV) in a slice, and an averaged effects of baclofen was used as n ϭ 1. Comparing the results from the two sets of experiments of baclofen control versus baclofen ϩ CGP7930, it was found that the widening effect of baclofen on the fEPSP was significantly potentiated by CGP7930, especially at low concentrations of baclofen (Fig. 3B) . On average, in baclofen control experiments, 0.1 M baclofen caused a small widening of the HW of the fEPSP (106.3 Ϯ 1.1% of control, P Ͻ 0.05, n ϭ 8), without affecting the slope of the fEPSP (102.5 Ϯ 2.5% of control, P Ͼ 0.05) (Fig. 2) . With the coapplication of 30 M CGP7930, baclofen at 0.1 M increased the HW by 20.6 Ϯ 3.0% (P Ͻ 0.01, Student's t test) (Fig. 3C ) more than the control. At 1 M baclofen, the HW of the fEPSP was widened by 36.6 Ϯ 2.5% (P Ͻ 0.001, n ϭ 8) in control experiments; but in the presence of CGP7930, the increase was 61.8 Ϯ 7.3%, which was significantly (P Ͻ 0.01) enhanced from the control. CGP7930 applied alone in the pretreatment period did not cause a significant change (103.0 Ϯ 1.2% of control, P Ͼ 0.05) to the HW. At higher concentrations of baclofen (3 and 10 M), no further increases in HW were recorded, indicating a saturation of the effect. However, the potentiation by CGP7930 was also found to be significant (P Ͻ 0.05) at 3 M baclofen (Fig. 3C) .
Changes in the excitatory drive by varying the stimulus intensity or during the application of 6-cyano-7-nitroquinoxaline-2,3-dione did not cause the widening of the fEPSP, but a reduction of GABA A R activation caused the slowing down of the returning phase of the fEPSP and hence the widening of the HW (data not shown). It is also known that the activation of N-methyl-D-aspartate receptors by the removal of extracellular magnesium ions produced a slow and protracted excitatory potential in CA1 that will cause widening of the fEPSP (Chen et al., 1999) . However, baclofen is not known to cause the removal of magnesium block of the N-methyl-Daspartate receptor channels, but baclofen is well demonstrated to reduce GABA release to inhibit synaptic inhibition (Bowery et al., 2002) . To confirm that the fEPSP HW widening by baclofen is due to reduced GABA A R-mediated synaptic inhibition, we tested the effects of baclofen when GABA A Rmediated synaptic inhibition was fully blocked. In the presence of 10 M bicuculline, baclofen at 1, 3, and 10 M was apparently prevented from causing the widening of the fEPSP, and CGP7930 failed to potentiate the effects (n ϭ 2, data not shown). However, in these experiments, the epileptiform activity present in the evoked responses caused "ripples" in the returning phase of the fEPSP, hindering accurate measurement of the fEPSP HW from a majority of the recordings, especially the ones from the proximal regions of the dendritic field. An alternative and more robust measurement is needed to examine the direct modulations of synaptic inhibition.
In the hippocampal CA1 pyramidal cells, stimulation of the Schaffer collateral-commissural fibers causes the monosynaptic GluR-mediated excitation, which is followed immediately by the delayed disynaptic GABA A R-mediated feedforward and feedback synaptic inhibition. The reduction of the delayed inhibition can affect the returning phase of the fEPSP and cause the widening. This synaptic inhibition can also manifest by inhibiting the second PS evoked by a paired stimuli with a short interval (interpulse interval ϭ 15 ms), known as the paired-pulse inhibition of the PS (Cornish and Wheal, 1989) . Paired-pulse recordings of the PS were therefore conducted to measure the strength of the delayed synaptic inhibition, and the effects of baclofen were compared with or without CGP7930.
In control slices with inhibition intact, the second pulse generates an inhibited PS, resulting in a paired-pulse ratio (PPR ϭ PS2/PS1) Ͻ1 (0.53 Ϯ 0.06, n ϭ 12) (Fig. 4A) . In these experiments, stimulus intensities were adjusted to evoke the PS of ϳ90% of the maximal amplitude. Although the PSs were recorded by electrodes positioned in the CA1 pyramidal cell layer, the fEPSP slopes were also monitored simultaneously by electrodes in the stratum radiatum (see Fig. 1 ). When synaptic excitation is not altered, changes in synaptic inhibition can be demonstrated by changes in the PPR of the PS.
As shown in Figs. 2 and 3 , it was found that low concentrations of baclofen caused few changes to the synaptic excitation. We, therefore, tested the effects of 0.1 and 1 M baclofen on the PPR of the PS. In control experiments, 0.1 M baclofen produced a small increase of the PPR (10.0 Ϯ 3.8%, n ϭ 6, P Ͻ 0.05, paired Student's t test) (Fig. 4, A and B, in the presence of 30 M CGP7930, the widening effects of 0.1 and 1 M baclofen were both enhanced, whereas 30 M CGP7930 alone had no effect on the fEPSP (dotted line). C, the averaged percentage changes in HW are shown for baclofen control experiments (F, n ϭ 8) and for CGP7930 treatment experiments (E, n ϭ 6). CGP7930 significantly potentiated the HW widening at 0.1, 1, and 3 M baclofen. C), indicating a slight reduction in the synaptic inhibitory strength. A further significant increase in PPR was found at 1 M baclofen (89.2 Ϯ 26.0%, P Ͻ 0.05) (Fig. 4, A and C) , which corresponds closely to the effects of baclofen on the fEPSP HW (see Fig. 3 ) and also agrees with the literature that baclofen reduces synaptic inhibition by inhibiting GABA release through the activation of presynaptic GABA B autoreceptors (Thompson and Gahwiler, 1992) The effects of the GABA B potentiator CGP7930 were then assessed on the PPR of the PS. After the coapplication of baclofen with 30 M CGP7930, it was found that larger increases in the PPR were observed at both 0.1 and 1 M baclofen (Fig. 4B) . A 9-fold (P Ͻ 0.05) and a 3-fold (P Ͻ 0.01) enhancement of the PPR were found at 0.1 and 1 M baclofen, respectively (Fig. 4C) . The GABA B R antagonist CGP55845 reversed the effects of baclofen but had no effects on the PPR on its own (data not shown). The GABA B R allosteric modulator CGP7930 alone also had no significant effects on PPR (Fig. 4C) . These results show that CGP7930 significantly potentiated the baclofen-induced suppression of the synaptic inhibition, despite the lack of effects by CGP7930 on baclofen-induced modulation of the synaptic excitation.
Apart from the selective modulation by CGP7930 on the synaptic inhibition, we also found that baclofen showed enhanced sensitivity for modulating the inhibitory event. As shown in Fig. 2 , baclofen at 0.1 and 1 M had no significant effects on the fEPSP slope, which measures synaptic excitation. However, both 0.1 and 1 M baclofen showed significant effects on the modulation of synaptic inhibition, measured by the increase in PPR of the PS (Fig. 4) . Taken together, it appears that the GABA B Rs that modulate the synaptic inhibition were more sensitive to baclofen, and their functions were selectively potentiated by CGP7930.
Discussion
The hippocampal CA1 neuronal network is composed of fast excitatory and inhibitory components mediated by the ionotropic GluRs and the GABA A receptors, respectively, as well as by various modulatory components. Immediately after the excitatory input, the fast synaptic inhibition is activated to reduce the excitation, keeping a fine balance between the excitation and the inhibition. The GABA B receptors can powerfully modulate both the excitatory and the inhibitory components by pre-and postsynaptic mechanisms (Thompson and Gahwiler, 1992) . In our experiments, we confirmed the inhibitory effects of baclofen on synaptic excitation, measured mainly as the fEPSP slope, and on delayed synaptic inhibition, measured by the paired-pulse inhibition of the PS. We have also found that baclofen showed higher potency for modulating the synaptic inhibition than the synaptic excitation in CA1, similar to an observation in CA3 (Lei and McBain, 2003) . More interestingly, when testing the effects of the GABA B allosteric modulator CGP7930, we observed potentiation of baclofen's effects on synaptic inhibition only. Baclofen's inhibitory effects on synaptic excitation were not enhanced by CGP7930. We have, therefore, observed in the hippocampal CA1 area a differential modulation of synaptic transmission by the GABA B allosteric modulator CGP7930, which also correlates with a differential sensitivity to baclofen of the two synaptic pathways.
The differential modulation by CGP7930 on synaptic transmission reported here is probably due to a different effect by this compound on the presynaptic autoreceptors located on the inhibitory GABA terminals compared with that on the presynaptic heterosynaptic receptors on the excitatory Glu terminals. Effects on postsynaptic GABA B Rs on CA1 cells would equally affect the measurements of both the excitatory and the inhibitory components so that a selective effect on the autoreceptors versus the heteroreceptors could explain the experimental results. Numerous electrophysiological and biochemical studies indicate pharmacological differences between presynaptic auto-and heteroreceptors, and between pre-and postsynaptic receptors in various brain tissues (Bowery et al., 2002; Bettler et al., 2004) . Differences between presynaptic auto-and heteroreceptors in the CA3 area of the hippocampus included the finding that GABA A receptor-mediated synaptic inhibition was more sensitive to baclofen (Lei and McBain, 2003) and to pertussis toxin and barium treatments (Thompson and Gahwiler, 1992) . In measuring GABA, Glu, and other neurotransmitter release, several agonists and antagonists displayed pharmacologically distinct potencies between the presynaptic GABA B auto-and heterosynaptic receptors (Bonanno and Raiteri, 1993; Teoh et al., 1996; Bonanno et al., 1997) . Now, for the first time, in the hippocampal CA1 area, we have demonstrated that the novel GABA B receptor-positive allosteric modulator, CGP7930, selectively potentiated baclofen-induced activation of presynaptic autoreceptors.
GABA B Rs are involved in many neuronal functions and diseases, and the GABA B R agonist baclofen has been used clinically to treat spasticity, pain, and addiction. However, agonist-induced side effects and tolerance have limited the jpet.aspetjournals.org therapeutic potential of baclofen. Based on considerable evidence pointing to the existence of pharmacologically distinct native GABA B R subtypes (Bowery et al., 2002; Bettler et al., 2004) , it was hoped that subtype-selective agonists and antagonists could dissociate their therapeutic effects from the side effects. However, to date, no subtype-selective agonists or antagonists were found. In particular, expression cloning of GABA B Rs failed to reveal pharmacologically distinct receptor subtypes (Kaupmann et al., 1998) , even though two major GABA B(1) isoforms were identified as 1a and 1b. Several intracellular mechanisms have also been shown to influence the GABA B R function, which include receptor G-protein coupling, type of G-proteins, G-protein effecter coupling, and subunit phosphorylation states (Couve et al., 2002; Bettler et al., 2004) . However, the existence of any subtypes of GABA B Rs is still uncertain.
The therapeutic utility of GABA B R modulation was further exploited recently by the discovery of GABA B R-positive allosteric modulators (Urwyler et al., 2001 (Urwyler et al., , 2003 and their in vivo potencies in behavioral experiments of reward (Smith et al., 2004; Slattery et al., 2005) and anxiety (Cryan et al., 2004) . In addition to the efficacy of the GABA B R-positive allosteric modulators in disease models, they were also found to be devoid of agonistic side effects. This profile enhanced the therapeutic potential of the GABA B R-positive allosteric modulators, but the underlying mechanisms remain largely unexplained, although the use of an allosteric modulator may reduce drug tolerance developed in patients using baclofen for a prolonged period (Abel and Smith, 1994) . Few studies have been conducted to examine the effects of the potentiators at the synaptic level and to elucidate their modulation of synaptic transmission. Our previous work (Chen et al., 2005b) showed that CGP7930 potentiated the baclofen-induced reduction in firing of ventral tegmental dopamine neurons and provided a mode of action for GABA B R potentiators in reducing the rewarding effects of cocaine. Now in the hippocampus, we have demonstrated a novel mechanism of the preferential modulation by CGP7930 on the synaptic inhibition in the CA1 area. Discussions on the relevance of in vitro concentrations and in vivo doses were attempted in our previous article (Chen et al., 2005b) and by Smith et al. (2004) . Our previous findings showed that 10 M CGP7930 was ineffective in experiments using brain slices and yet a 100 M concentration was insoluble in ACSF, so the optimal concentration of 30 M was used in the present experiments. Other studies using native brain tissues also indicated that the effective range of CGP7930 was between 10 and 100 M (Onali et al., 2003; Urwyler et al., 2005) . Tissue penetration and compound solubility may have affected the apparent potency of the compound compared with that in in vitro experiments using membrane preparations (EC 50 of 1-5 M) (Urwyler et al., 2001) . After in vivo administration of an effective dose (30 mol/kg) of CGP7930, brain concentrations of the compound were estimated to be approximately 300 nmol/kg 1 h later (Smith et al., 2004) . A higher brain concentration may be expected 10 to 15 min after compound administration, when the behavioral experimental procedures were carried out (Carai et al., 2004; Smith et al., 2004) .
GABA B R potentiators have no intrinsic agonistic effects and hence require the presence of an agonist to exert their actions. Because of the extrasynaptic location of the GABA B Rs (Scanziani, 2000) , endogenously released GABA may need to escape the synaptic cleft to reach the presynaptic GABA B Rs. In our experiments, we used the exogenous ligand, baclofen. As a result, both the presynaptic GABA B auto-and heterosynaptic receptors were exposed to the same concentrations of the agonist, and the effects on both pathways were recorded simultaneously using a multielectrode system. The effects of low concentrations of baclofen probably represent more closely the physiological effects of GABA B R activation. In our experiments, the significant effects of CGP7930 were indeed found when it was coapplied with low concentrations of baclofen. Accordingly, the differential modulation by CGP7930 on synaptic inhibition versus synaptic excitation is not due to the accessibility of the endogeneously released GABA to the presynaptic GABA B auto-versus heterosynaptic receptors but to the selective sensitivity of the presynaptic GABA B autoreceptors to the positive allosteric modulator.
Our work has thus revealed a novel pattern of allosteric modulation on native GABA B Rs in their modulation of synaptic transmission. The differential potentiation of GABA B Rmediated functions by CGP7930 provides a synaptic mechanism by which the GABA B potentiators may exert their in vivo efficacies without the untoward side effects of the GABA B R agonists, in support of GABA B potentiators as an exciting new and better therapeutic alternative to GABA B agonists.
